10/28/2026
Pharma giants invest billions in psychedelics despite hurdles
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
Topic archive
investment
8 stories
10/21/2026
Psyence BioMed finalizes $2.6M investment in PsyLabs
Psyence BioMed invests in PsyLabs following milestone achievements.
10/5/2026
AdvisorShares Trust holds 6.78% stake in Psyence Biomedical
The investment firm reports significant ownership in Psyence Biomedical as of September 2026.
9/24/2026
Psyence Biomedical invests $5M in ibogaine research
Psyence Biomedical's $5M investment aims to advance ibogaine program in the U.S.
9/23/2026
Psyence BioMed announces ibogaine investment and trial plans
Psyence BioMed to invest $5M in PsyLabs, plans Texas ibogaine trial.
9/23/2026
Psyence Biomed announces ibogaine investment
The company aims to advance ibogaine research for mental health.
9/23/2026
Psyence Biomedical expands with Texas ibogaine unit
Company invests $5 million in PsyLabs for ibogaine research and production.
7/19/2026
Psychedelic drugs market sees positive growth signal
Investment interest grows in psychedelics for mental health treatment.